Detalhe da pesquisa
1.
K2P2.1 is a regulator of inflammatory cell responses in idiopathic inflammatory myopathies.
J Autoimmun
; 142: 103136, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37935063
2.
Prdx4 limits caspase-1 activation and restricts inflammasome-mediated signaling by extracellular vesicles.
EMBO J
; 38(20): e101266, 2019 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31544965
3.
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.
Brain
; 145(5): 1711-1725, 2022 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661859
4.
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses.
J Neuroinflammation
; 19(1): 220, 2022 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36071461
5.
Cladribine treatment improves cortical network functionality in a mouse model of autoimmune encephalomyelitis.
J Neuroinflammation
; 19(1): 270, 2022 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36348455
6.
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
Mult Scler
; 28(2): 257-268, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33975489
7.
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
J Neurol Neurosurg Psychiatry
; 92(9): 1007-1013, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33712515
8.
Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Mult Scler
; 27(12): 1960-1964, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34165361
9.
Patients with a relapsing course of steroid-responsive encephalopathy associated with autoimmune thyroiditis exhibit persistent intrathecal CD4+ T-cell activation.
Eur J Neurol
; 28(4): 1284-1291, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33230897
10.
Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas.
Mult Scler
; 30(7): 897-898, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385204
11.
Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis.
Mult Scler
; : 13524585241260564, 2024 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38877846
12.
Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
Mult Scler
; 25(5): 661-668, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29532745
13.
Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination.
Int J Mol Sci
; 20(23)2019 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31795084
14.
Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Mult Scler
; 22(9): 1235-41, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26980848
15.
ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
BMC Neurol
; 16: 34, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26966029
16.
Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
Neurology
; 103(2): e209574, 2024 Jul 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38870471
17.
Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-γ.
Mult Scler
; 24(13): 1783-1784, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30307361
18.
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine.
Cells
; 12(9)2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37174643
19.
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.
Neurol Neuroimmunol Neuroinflamm
; 10(3)2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37041077
20.
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
J Neurol
; 269(5): 2806-2818, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34999925